Noroplex (Dimethyl Fumarate)

Dimethyl fumarate activates the Nrf2 signaling pathway, which increases the production of antioxidant and cytoprotective proteins. This reduces oxidative stress and inflammation, leading to neuroprotective effects in multiple sclerosis and improvement of skin lesions in psoriasis.

The specific dose of Noroplex is determined by the prescribing clinician based on the patient’s condition, disease severity, and individual response. Healthcare professionals follow approved dosing guidelines and may adjust the regimen during treatment.

Safety data for dimethyl fumarate in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting Noroplex.

To request Noroplex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with other disease‑modifying therapies, dimethyl fumarate offers oral administration and a distinct mechanism via Nrf2 activation. It has a favorable efficacy profile for reducing relapse rates, but its safety considerations, such as lymphopenia and flushing, differ from agents like interferon‑beta or fingolimod.

Noroplex should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its stability and potency throughout its shelf life.

Noroplex is taken orally, usually with food to lessen gastrointestinal discomfort. The tablets (or capsules) are swallowed whole with a glass of water and should be taken at the same time each day as directed by the prescriber.

The most serious risks include severe lymphopenia that can predispose to opportunistic infections such as progressive multifocal leukoencephalopathy (PML), significant liver injury, and rare severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for these events.

Noroplex is contraindicated in patients with known hypersensitivity to dimethyl fumarate or any excipients, those with active serious infections, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of severe lymphopenia.